European Cancer Patient Coalition
European Cancer Patient Coalition (ECPC) is a Brussels-based non-profit founded in 2003 that serves as the unified voice of cancer patients across Europe, providing policy advocacy at EU institutions, patient-facing educational tools, and participation in EU-funded clinical research consortia.
- Company typePrivate
- Founded2003
- HeadquartersBrussels, Belgium
- Headcount11–50
- GTM typeB2B
- OfferingServices
What European Cancer Patient Coalition does
The European Cancer Patient Coalition (ECPC) is a non-profit patient advocacy organisation (AISBL under Belgian law) headquartered in Brussels, founded in 2003 to serve as the unified voice of cancer patients across Europe. Its core customers are cancer patients, their families, and the national/regional patient organisations that constitute ECPC's membership; secondary stakeholders include cancer researchers, healthcare professionals, and EU policymakers. The organisation delivers value through three integrated activities: (i) pan-European policy advocacy at the European Commission, European Parliament, Council of the EU, and the European Medicines Agency on issues including access to medicines, immuno-oncology, biosimilars, health technology assessment, right-to-be-forgotten, employment rights, and survivorship; (ii) a curated suite of patient-facing educational tools — Clinical Trials Database, ESMO Cancer Patient Guides, Immuno-Oncology Portal, Personalised Medicine and Biosimilars e-modules, Nutrition Booklet, and Cancer Associated Thrombosis Tool — distributed free through ecpc.org; and (iii) participation as coordinator or partner in EU-funded (Horizon 2020, Horizon Europe, IMI2) clinical and translational research consortia such as ImmunoSABR, SALVOVAR, Immune-Image, and Pal-Cycles, alongside pharmaceutical industry supporters including Roche, Bayer, Janssen, Novartis and Pfizer. Its revenue model is non-commercial: it derives operating income from EU research grants, membership fees, donations, and industry partner support, without selling products or services. The organisation is governance-led, run by a Board elected by its membership, with a small Brussels-based secretariat (11–50 employees) including President Ken Mastris and Director Antonella Cardone. ECPC celebrated its 20th anniversary with a Brussels Congress in June 2023.
European Cancer Patient Coalition firmographics
Firmographics- Name
- European Cancer Patient Coalition
- Legal name
- European Cancer Patient Coalition (ECPC) AISBL
- Website
- https://ecpc.org
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- European Cancer Patient Coalition (ECPC) is a Brussels-based non-profit founded in 2003 that serves as the unified voice of cancer patients across Europe, providing policy advocacy at EU institutions, patient-facing educational tools, and participation in EU-funded clinical research consortia.
- Ownership category
- akta.pro rank
European Cancer Patient Coalition industry classification
Industry- Product category
- Patient Advocacy Services
- NAICS
- Professional Organizations (81392)
- SIC
- Services-Membership Organizations (8600), Services-Educational Services (8200)
- akta.pro primary industry
- Regulatory Submissions & Clinical Content Management (eCTD/Publishing) (HLACAOAN)
Keywords
Where European Cancer Patient Coalition is headquartered
LocationHeadquarters
- HQ city
- Brussels
- HQ country
- Belgium
- HQ region
- Europe
Offices1 record
Markets served
European Cancer Patient Coalition business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Distribution channels4 records
Marketing channels5 records
European Cancer Patient Coalition product offering
Product offeringCore offering
ECPC is a non-profit cancer patient umbrella organization that represents the voice of cancer patients at the European level. Its core offering is patient advocacy delivered through EU policy representation, development and free distribution of patient educational tools and e-modules, training through the Cancer Advocacy Academy, and partnership in EU-funded oncology research consortia.
Product overview
The European Cancer Patient Coalition (ECPC) is a patient advocacy organization, not a technology product company. ECPC provides a unified voice for cancer patients across Europe, offering educational resources, tools, and e-modules for patients. The organization's portfolio includes patient-facing resources such as the Clinical Trials Database, ESMO Cancer Patient Guides, Nutrition Booklet, Immuno-oncology Portal, and various e-modules on genetics, biosimilars, and health technology assessment. ECPC also participates in EU-funded research projects including Immuno-Image (imaging immune cells for immunotherapy), ImmunoSABR (immunotherapy combined with radiotherapy for lung cancer), SALVOVAR (ovarian cancer treatment), and Pal-Cycles (palliative care communication). These research projects are collaborative academic initiatives, not commercial products.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Trials Database Online database that helps cancer patients across Europe locate and understand clinical trials relevant to their condition.
- ESMO Cancer Patient Guides Patient-friendly guides developed with the European Society for Medical Oncology to help cancer patients understand their diagnosis and treatment options.
- Immuno-oncology Portal (IOP) Web-based educational portal providing patients and advocates with information on immuno-oncology treatments and the science behind them.
- Personalised Medicine Tool Educational resource explaining personalised medicine concepts to cancer patients, including diagnostics, targeted therapies, and access considerations.
- Nutrition Booklet Booklet providing cancer patients with guidance on nutrition during and after cancer treatment.
- Biosimilars E-module E-learning module explaining biosimilar medicines to cancer patients and advocates to support informed decision-making.
- Genetics and Genomics Testing E-Module E-learning module explaining genetic and genomic testing in cancer to patients and advocates.
- Health Technology Assessment E-Module E-learning module introducing patients and advocates to Health Technology Assessment processes used in reimbursement decisions.
- Biobanking Tool Educational tool explaining biobanking and its role in cancer research to patients and advocates.
- Bone Health Tool Educational tool addressing bone health issues faced by cancer patients, particularly those affected by bone metastases or treatment-related bone loss.
- Cancer Associated Thrombosis (CAT) Tool Educational tool informing cancer patients and clinicians about cancer-associated thrombosis risk, prevention, and management.
- Non-Melanoma Skin Cancer Web Hub Online hub providing information and resources for patients with non-melanoma skin cancer.
- Cancer Advocacy Academy Training programme including a Social Media Manual to build advocacy capacity among European cancer patient advocates and member organizations.
Companies that use European Cancer Patient Coalition
Customer profileSegments4 records
Ideal customer profiles3 records
European Cancer Patient Coalition technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature5 records
European Cancer Patient Coalition partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- European Medicines Agency (EMA)coreECPC has formal engagement with EMA as a patient organization representative, participating in EMA procedures and providing patient perspective on medicines regulation.
- Maastricht UniversitycoreLead coordinator of ImmunoSABR project - a European clinical trial combining immunotherapy and stereotactic ablative radiotherapy for lung cancer. Funded by Horizon 2020 Grant No 733008.
- Lyon University Hospital (HCL)coreLead coordinator of SALVOVAR project for ovarian cancer treatment research. Partner in Horizon programme clinical project involving six countries (UK, France, Italy, Czech Republic, Israel, Netherlands) and 100 recruitment centers.
- Stichting VUMCcorePartner in Immune-Image project funded by IMI2 under grant agreement No 831514, developing specific imaging of immune cell dynamics using novel tracer strategies for cancer immunotherapy.
- Stichting Radboud Universitair Medisch CentrumcoreLead coordinator of Pal-Cycles project (Grant Agreement No 101057243) - a Horizon Research and Innovation Action on patient-centred palliative cancer care in community settings, running 2022-2027.
- Roche, Bayer, Janssen, Novartis, PfizerminorPharmaceutical company partners in the Immune-Image project, providing industry perspective on immune imaging tracers and contributing to the IMI2 public-private partnership.
- Technical University of Denmark, Academic Hospital Maastricht, KU Leuven, and 16 other European institutionscoreResearch partners in ImmunoSABR consortium including academic hospitals and universities across Europe contributing to clinical trial on immunotherapy and radiotherapy for lung cancer.
- European Association of Palliative CareminorPartner organization in Pal-Cycles project bringing palliative care expertise to the consortium focused on improving continuity of cancer care in community settings.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
European Cancer Patient Coalition competitors and assessment
Company assessmentDirect peers
- European Cancer Organisation: Multi-stakeholder European cancer organisation engaging EU policymakers, healthcare professionals, and patient groups. Comparable to ECPC as the principal non-disease-specific cancer policy platform in Brussels, with overlapping engagement on Europe's Beating Cancer Plan.
- EURORDIS - Rare Diseases Europe: Brussels-based coalition representing rare disease patient organisations across Europe. Directly comparable governance, funding model, and policy-advocacy model to ECPC; operates as a peer patient coalition within EMA procedures and EU rare disease policy.
- International Alliance of Patients' Organizations (IAPO): Global alliance of patient organisations across disease areas. Comparable to ECPC in mission (patient voice in policy, capacity building for member organisations) and governance, with broader geographic scope but overlapping policy advocacy frameworks.
- European Patients' Forum: Brussels-based umbrella coalition of European patient organisations across disease areas. Directly comparable to ECPC in structure (membership coalition, EU policy advocacy, EU funding dependency) and operates as a peer voice in EU health policy consultations alongside ECPC.
Broad incumbents
- Cancer Research UK: UK-based cancer charity combining research funding, patient information, and policy advocacy. Comparable in advocacy and patient-information functions but with a much larger research-grant operation and primarily UK (rather than EU) orientation.
- American Cancer Society: US-based nationwide voluntary health organisation covering cancer advocacy, patient support, and research funding. Comparable mission and operating model to ECPC but at far greater scale and with primarily US geographic scope.
Emerging players
- European Public Health Alliance (EPHA): Brussels-based NGO coalition working on broader European public health policy. Comparable to ECPC in EU advocacy infrastructure and membership-coalition model, with a wider disease scope and overlapping engagement on EU health legislation.
- Europa Donna - The European Breast Cancer Coalition: European advocacy coalition focused specifically on breast cancer. Member of the ECPC network but operates as a focused-disease counterpart, with comparable EU policy engagement on screening, access, and research funding.
Others
- International Agency for Research on Cancer (IARC/WHO): WHO specialised agency for cancer research headquartered in Lyon. Comparable to ECPC's research-coordination and dissemination functions but as a UN intergovernmental body rather than a patient-organisation coalition; overlaps on European cancer-research agenda-setting.
- European Federation of Pharmaceutical Industries and Associations (EFPIA): Brussels-based trade association representing the European pharmaceutical industry. Frequently engages ECPC as a counterparty in EU policy discussions on access to medicines, HTA, and clinical trials — comparable in Brussels policy arena but representing industry rather than patient perspective.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
European Cancer Patient Coalition social profiles
Digital presenceEuropean Cancer Patient Coalition financial estimates
Financial estimateRevenue estimate
Valuation estimate
European Cancer Patient Coalition leadership team
Management profileNumber of profiles
Profiles4 records
European Cancer Patient Coalition funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
European Cancer Patient Coalition M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about European Cancer Patient Coalition
What does European Cancer Patient Coalition do?
ECPC is a non-profit cancer patient umbrella organization that represents the voice of cancer patients at the European level. Its core offering is patient advocacy delivered through EU policy representation, development and free distribution of patient educational tools and e-modules, training through the Cancer Advocacy Academy, and partnership in EU-funded oncology research consortia.
Is European Cancer Patient Coalition a public or private company?
European Cancer Patient Coalition is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was European Cancer Patient Coalition founded?
European Cancer Patient Coalition was founded in 2003. It employs 11 to 50 people.
Where is European Cancer Patient Coalition based?
European Cancer Patient Coalition is headquartered in Brussels, Belgium, in the Europe region.
Who are European Cancer Patient Coalition's main competitors?
Direct peers on record are European Cancer Organisation, EURORDIS - Rare Diseases Europe, International Alliance of Patients' Organizations (IAPO) and European Patients' Forum. Broad incumbents are Cancer Research UK and American Cancer Society. Emerging players are European Public Health Alliance (EPHA) and Europa Donna - The European Breast Cancer Coalition. Others are International Agency for Research on Cancer (IARC/WHO) and European Federation of Pharmaceutical Industries and Associations (EFPIA).
Does European Cancer Patient Coalition have an API?
No public API is recorded for European Cancer Patient Coalition.
What industry is European Cancer Patient Coalition in?
European Cancer Patient Coalition's product category is Patient Advocacy Services. Its primary akta.pro industry code is HLACAOAN, Regulatory Submissions & Clinical Content Management (eCTD/Publishing). Its NAICS code is 81392 and its SIC code is 8600.